ANI Pharmaceuticals is pivoting growth toward its Cortrophin Gel franchise as setbacks in its retina business are expected to weigh on 2025 performance. Management and the market are looking to 2026 for recovery, contingent on specialty product momentum and a strategic portfolio reset to restore growth.
ANI Pharmaceuticals is pivoting growth toward its Cortrophin Gel franchise as setbacks in its retina business are expected to weigh on 2025 performance. Management and the market are looking to 2026 for recovery, contingent on specialty product momentum and a strategic portfolio reset to restore growth.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
